TUSTIN, Calif., April 11 /PRNewswire-FirstCall/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical
company developing targeted therapies for the treatment of cancer and
hepatitis C virus infection (HCV), today announced that the following
preclinical abstracts will be the subject of oral and poster presentations
at the 2008 Annual Meeting of the American Association for Cancer Research
(AACR), being held April 12-16, 2008 in San Diego:
-- "Targeting mutant p53 protein and tumor vasculature: An effective
combination therapy for advanced breast tumors" (Abstract #2341, New
Targets 1: Mechanisms Session) - Poster session scheduled for Monday,
April 14, 2008 from 8:00 am to 12:00 pm.
-- "An immunocytokine that binds to phosphatidylserine generates an
effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor
Vaccines Session) - Poster session scheduled for Monday, April 14,
2008 from 1:00 pm to 5:00 pm.
-- "Combination of a monoclonal anti-phosphatidylserine antibody with
docetaxel strongly inhibits the growth and metastasis of
hormone-refractory prostate cancers in mice" (Abstract #2551, New
Approaches to Biological Therapy Session) - Oral presentation
scheduled for Monday, April 14, 2008 at 2:10 pm.
-- "Antibody targeting of phosphatidylserine produces a cytokine
microenvironment that enhances innate anti-tumor immune responses"
(Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics
Session) - Poster session scheduled for Tuesday, April 15, 2008 from
8:00 am to 12:00 pm.
Abstracts and information abou
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved